Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XRD-0394 and Radiation Therapy in High Grade Gliomas
NCT06829173Phase 1Recruiting
- Sponsor
- NYU Langone Health
- Start
- Nov 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xrd-0394 in glioma (4 arms), sponsored by NYU Langone Health. Primary endpoint: Dose-Limiting Toxicities at Day 108. Started Nov 2025; status: recruiting.
02
Drugs
xrd-0394
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06829173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829173.